|
|
||||||||
Department of Chemistry, University of Illinois, Urbana, Illinois
Division of Radiation Sciences, Mallinckrodt Institute, Washington University Medical School, St. Louis, Missouri
Correspondence: For reprints contact: John A. Katzenallenbogen, Department of Chemistry, University of Illinois, 461 Roger Adams Laboratory, Box 37, 1209 West California St., Urbana, IL 61801.
ABSTRACT
We have synthesized six androgens labeled with 18F as potential imaging agents for prostatic cancer. These include 16ß-fluorine-substituted testosterone, dihydrotestosterone and mibolerone, 16
- and 16ß-fluorine substituted 7
-methyl-19-nortestosterone, and 20-fluoro-R1881 (metribolone). All of the radiochemical preparations proceeded in satisfactory yield, giving material with adequately high effective specific activity for the in vivo studies. In the tissue distribution studies in diethylstilbestrol-treated male rats, high selective uptake by the prostate was observed that ranged from 0.39% to 1.21% injected dose (ID)/g at 1 hr and 0.20 to 0.47 at 4 hr, with prostate-to-blood and prostate-to-muscle ratios ranging from 3.28 to 9.45, respectively, at 1 hr and 4.06 to 35.0, respectively, at 4 hr. Those compounds that are likely to be metabolized rapidly showed lower prostate uptake but higher uptake selectivity at 4 hr; at earlier times, uptake selectivities were more comparable. Compounds with a 16ß-fluorine substituent showed extensive metabolic defluorination, resulting in ca.50% of the dose being deposited in bone at 4 hr. This is consistent with a 16
-hydroxylation process that may proceed rapidly with these compounds, but would be retarded by a 17
-methylation, blocked by inversion of stereochemistry at C-16, and would not affect fluorine at the C-20 position. These fluoroandrogens, together with 20-fluoromibolerone described previously, are the first positron-emitting androgens to show high affinity and selective uptake by androgen target tissues in vivo, and they may be useful as in vivo prostate imaging agents in man.
This article has been cited by other articles:
![]() |
E. E. Parent, C. S. Dence, T. L. Sharp, M. J. Welch, and J. A. Katzenellenbogen 7{alpha}-18F-Fluoromethyl-Dihydrotestosterone and 7{alpha}-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone-Binding Globulin for Steroidal Radiopharmaceuticals J. Nucl. Med., June 1, 2008; 49(6): 987 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. B. Zanzonico, R. Finn, K. S. Pentlow, Y. Erdi, B. Beattie, T. Akhurst, O. Squire, M. Morris, H. Scher, T. McCarthy, et al. PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer J. Nucl. Med., November 1, 2004; 45(11): 1966 - 1971. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Scheffel and M. G. Pomper PET Imaging of GRP Receptor Expression in Prostate Cancer J. Nucl. Med., August 1, 2004; 45(8): 1277 - 1278. [Full Text] [PDF] |
||||
![]() |
S. M. Larson, M. Morris, I. Gunther, B. Beattie, J. L. Humm, T. A. Akhurst, R. D. Finn, Y. Erdi, K. Pentlow, J. Dyke, et al. Tumor Localization of 16{beta}-18F-Fluoro-5{alpha}-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer J. Nucl. Med., March 1, 2004; 45(3): 366 - 373. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |